These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31551655)

  • 1. Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.
    Zhang H; Wang L; Fan Y; Yang L; Wen X; Liu Y; Liu Z
    Neuropsychiatr Dis Treat; 2019; 15():2137-2149. PubMed ID: 31551655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.
    Jethwa KD; Onalaja OA
    BJPsych Open; 2015 Jun; 1(1):27-33. PubMed ID: 27703720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B
    Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
    Iketani R; Kawasaki Y; Yamada H
    Biol Pharm Bull; 2017; 40(11):1976-1982. PubMed ID: 29093347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review.
    Colijn MA
    J Neuropsychiatry Clin Neurosci; 2024 Jul; ():0. PubMed ID: 39034670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis.
    Iketani R; Furushima D; Imai S; Yamada H
    Parkinsonism Relat Disord; 2020 Sep; 78():82-90. PubMed ID: 32755800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine in the treatment of psychosis in Parkinson's disease.
    Shotbolt P; Samuel M; David A
    Ther Adv Neurol Disord; 2010 Nov; 3(6):339-50. PubMed ID: 21179595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G
    Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
    Friedman JH; Factor SA
    Mov Disord; 2000 Mar; 15(2):201-11. PubMed ID: 10752567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism.
    Chen JJ; Hua H; Massihi L; Portillo I; Alipour A; Ondo W; Dashtipour K
    J Neuropsychiatry Clin Neurosci; 2019; 31(3):188-195. PubMed ID: 30848989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.